Brenda Cirincione

Clinical relevance of anti‐exenatide antibodies: safety, efficacy and cross‐reactivity with long‐term treatment

Mark Fineman, Kenneth Mace, M. Diamant et al. · Diabetes Obesity and Metabolism · 2012 · 148 citations

Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing

Mark Fineman, Shawn Flanagan, Kristin Taylor et al. · Clinical Pharmacokinetics · 2010 · 134 citations

Pharmaceutical Science, Pharmacological Study, Pharmacodynamics +8

Use of Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Phase 2 and 3 Dosing Strategies for Doripenem

Sujata M. Bhavnani, Jeffrey Hammel, Brenda Cirincione et al. · Antimicrobial Agents and Chemotherapy · 2005 · 123 citations · Full text

Pharmacotherapy, Pharmacokinetic-pharmacodynamic Target Attainment, Dosing Strategies +17

Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections

Alison Meagher, Julie Passarell, Brenda Cirincione et al. · Antimicrobial Agents and Chemotherapy · 2007 · 111 citations · Full text

Predominant Pathogens, Health Sciences, Skin Testing +14

Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Intra-Abdominal Infections

Julie Passarell, Alison Meagher, Kathryn Liolios et al. · Antimicrobial Agents and Chemotherapy · 2007 · 103 citations · Full text

Predominant Pathogens, Antimicrobial Stewardship, E. Coli Pathogens +12